RedShift BioAnalytics
RedShift BioAnalytics develops and manufactures MMS-based analytical instruments (Aurora TX, HaLCon) that measure protein structure, stability, and titer for biopharmaceutical R&D and bioprocess manufacturing, sold via direct enterprise sales to pharma, biotech, CRO/CMO, academic, and government labs.
- Company typePrivate
- Founded2005
- HeadquartersBurlington, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RedShift BioAnalytics does
RedShift BioAnalytics, Inc. (operating as RedShiftBio) is a privately held, Delaware-incorporated analytical instrumentation company founded in 2005 and headquartered at 80 Central Street, Boxborough, Massachusetts. It develops and manufactures bioanalytical tools based on its proprietary Microfluidic Modulation Spectroscopy (MMS) platform, which pairs a tunable quantum cascade laser (at least ~1,000x more intense than conventional IR sources) with a microfluidic flow cell to enable real-time background subtraction and ultra-sensitive measurement of protein secondary structure across a 0.1 to >200 mg/mL concentration range with minimal buffer interference. Its product portfolio includes the first-generation AQS³pro MMS instrument, the next-generation Aurora TX automated protein analyzer for biophysical characterization in formulation buffer, the HaLCon real-time protein titer system for bioprocess monitoring, and the delta software package for automated spectral and secondary-structure analysis. Customers use Aurora TX and HaLCon to detect subtle (<2%) structural changes in monoclonal antibodies, antibody-drug conjugates, biosimilars, RNA, peptides, and vaccines, with ~90% non-destructive sample recovery.
The company sells primarily through a direct enterprise field-sales motion with demo-based engagement, supported by an extensive library of application notes, peer-reviewed publications, webinars, and conference participation (e.g., PepTalk, PEGS, BPI Digital). Revenue is generated mainly through capital-equipment sales of Aurora TX and HaLCon instruments to pharmaceutical, biotechnology, CRO/CMO, academic, and government customers, with a smaller recurring component from the integrated delta software platform. Named end users include Pfizer, Amgen, ImmunoGen, Celldex Therapeutics, KBI Biopharma (Elion Labs), the National Institutes for Food and Drug Control of China, and Clark University. The company has raised approximately $71.6 million in disclosed venture funding across nine rounds since 2006, including a $20 million Series E led by Illumina Ventures in October 2021 and follow-on bridge rounds in 2024 and 2025.
RedShift's customer segments are diversified across biopharma R&D, bioprocess manufacturing, contract research/manufacturing, and regulatory/academic use cases, with strategic investors including Illumina Ventures, Waters Corporation, and Technology Venture Partners. The company is led by CEO Julien Bradley and co-founder/CTO Eugene Ma, supported by VPs of engineering and product development. Operating geographies are global rather than US-only, with a documented installation in China's national biologics QC infrastructure.
RedShift BioAnalytics firmographics
Firmographics- Name
- RedShift BioAnalytics
- Legal name
- RedShift BioAnalytics, Inc.
- Website
- https://redshiftbio.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RedShift BioAnalytics develops and manufactures MMS-based analytical instruments (Aurora TX, HaLCon) that measure protein structure, stability, and titer for biopharmaceutical R&D and bioprocess manufacturing, sold via direct enterprise sales to pharma, biotech, CRO/CMO, academic, and government labs.
- Ownership category
- akta.pro rank
RedShift BioAnalytics industry classification
Industry- Product category
- Bioanalytical Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)
Keywords
Where RedShift BioAnalytics is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RedShift BioAnalytics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Analytical Instrumentation Sales: Sale of Aurora TX and HaLCon analytical instruments for protein/biomolecule characterization in biopharmaceutical R&D and manufacturing
- Software/Subscription Services: Delta software for data analysis, integrated into Aurora TX platform for automated protein structural analysis
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
RedShift BioAnalytics product offering
Product offeringCore offering
RedShift BioAnalytics develops, manufactures, and sells analytical instruments based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology for protein and biomolecule structural characterization. The product portfolio includes the Aurora TX automated protein analyzer, the HaLCon real-time titer measurement system, and the earlier AQS³pro instrument, supported by the delta software for spectral analysis. These instruments are used by biopharmaceutical R&D and manufacturing teams to detect subtle structural changes in monoclonal antibodies, biosimilars, ADCs, RNA, and vaccines.
Product overview
RedShift BioAnalytics offers a portfolio of analytical instruments for protein and biomolecule analysis based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology. The core product line includes Aurora TX (a next-generation automated protein analyzer for biophysical characterization), HaLCon (a real-time titer measurement system for bioprocess analytics), and the earlier AQS³pro platform. These instruments are supported by the delta software package for automated spectral analysis. The MMS technology uses quantum cascade laser sources and microfluidic flow cells to measure protein secondary structure, stability, aggregation, similarity, and quantitation with high sensitivity across wide concentration ranges without buffer interference.
Differentiator
Problem solved
Functional benefit
Brands
- Aurora TX: Next-generation fully-automated protein analyzer for biomolecular structure, binding and stability measurement.
- HaLCon
- AQS³pro
Products and services
- Aurora TX Next-generation automated protein analyzer powered by MMS technology for biopharmaceutical R&D and manufacturing teams. Detects subtle structural changes in biomolecules that impact function and developability, measured directly in formulation buffer. Utilizes quantum cascade laser (QCL) and microfluidic flow cell technology.
- HaLCon Automated protein titer measurement system for bioprocessing. Delivers HPLC-level accuracy to guide timely process decisions without offline bottlenecks. Measures protein concentration directly during manufacturing.
- AQS³pro First-generation MMS instrument. Novel infrared spectroscopy tool that measures protein secondary structure in a non-destructive manner, enabling subsequent characterization and analysis with approximately 90% sample recovery.
- delta Software Integrated software package for the Aurora TX platform that performs automated spectral analysis and second derivative processing to elucidate protein structural composition. Includes a built-in protein library and is used for higher-order structure (HOS) analysis and structural population monitoring.
Companies that use RedShift BioAnalytics
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
RedShift BioAnalytics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RedShift BioAnalytics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights6 records
RedShift BioAnalytics competitors and assessment
Company assessmentDirect peers
- Unchained Labs: Unchained Labs develops protein analytical instruments (e.g., Uncle, Stunner, Freeslate) for biologics formulation, stability, and biophysical characterization. It directly competes with RedShift in protein therapeutic analytics targeting similar biopharma R&D and formulation customers.
- Waters Corporation: Waters is a global leader in liquid chromatography and mass spectrometry for protein characterization, and owns Wyatt Technology (light scattering for macromolecules). Waters is also a strategic investor in RedShift across two funding rounds, making it both a peer and a partner.
- Repligen Corporation: Repligen provides bioprocess analytics and chromatography solutions for biologics manufacturing. Its at-line and online PAT offerings compete directly with HaLCon in real-time bioprocess titer and protein monitoring for CDMOs and biopharma manufacturers.
- Applied Photophysics: Applied Photophysics specializes in Circular Dichroism (CD) spectrometers for protein secondary structure and stability analysis. Its Chirascan platform is one of the legacy techniques (alongside FTIR) that MMS is designed to displace or complement in biopharma workflows.
Broad incumbents
- Bruker Corporation: Bruker is a broad analytical instrumentation incumbent offering NMR, FTIR, mass spectrometry, and biophysical characterization tools used in protein therapeutics R&D. While not specifically QCL-microfluidic, its spectroscopy portfolio overlaps with MMS use cases in structural biology.
- Cytiva (Danaher): Cytiva offers a broad bioprocessing portfolio including ÄKTA systems, sensors, and PAT tools for biologics manufacturing. Its bioprocess analytics suite overlaps with RedShift's HaLCon use case in CDMO and biopharma manufacturing settings.
- Agilent Technologies: Agilent manufactures analytical instruments including FTIR, UV-Vis, and biopharma LC/MS solutions used in protein characterization. Its broad spectroscopy and chromatography portfolio competes indirectly with MMS across structural biology workflows.
- Thermo Fisher Scientific: Thermo Fisher provides a comprehensive analytical instrument portfolio including FTIR (Nicolet), CD spectroscopy, and biopharma-focused tools. It is a deep incumbent across nearly every workflow where MMS competes, with vastly greater sales and service reach.
- Sartorius AG: Sartorius offers bioprocess solutions including sensors and PAT analytics for upstream and downstream bioprocessing. Its IncPAT platform overlaps with HaLCon's positioning in real-time bioprocess monitoring for biologics manufacturing.
Emerging players
- Fluidic Analytics: Fluidic Analytics develops microfluidic-based protein interaction analysis tools (Fluidity One) targeting similar protein characterization use cases. Its microfluidic platform intersects with RedShift's MMS microfluidic flow cell approach, but focuses on interaction/sizing rather than secondary structure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
RedShift BioAnalytics social profiles
Digital presenceRedShift BioAnalytics financial estimates
Financial estimateRevenue estimate
Valuation estimate
RedShift BioAnalytics leadership team
Management profileNumber of profiles
Profiles4 records
RedShift BioAnalytics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RedShift BioAnalytics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RedShift BioAnalytics
What does RedShift BioAnalytics do?
RedShift BioAnalytics develops, manufactures, and sells analytical instruments based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology for protein and biomolecule structural characterization. The product portfolio includes the Aurora TX automated protein analyzer, the HaLCon real-time titer measurement system, and the earlier AQS³pro instrument, supported by the delta software for spectral analysis. These instruments are used by biopharmaceutical R&D and manufacturing teams to detect subtle structural changes in monoclonal antibodies, biosimilars, ADCs, RNA, and vaccines.
Is RedShift BioAnalytics a public or private company?
RedShift BioAnalytics is a private company. It is classified as venture growth investor backed and is currently operating.
When was RedShift BioAnalytics founded?
RedShift BioAnalytics was founded in 2005. It employs 11 to 50 people.
Where is RedShift BioAnalytics based?
RedShift BioAnalytics is headquartered in Burlington, United States, in the North America region.
How does RedShift BioAnalytics make money?
Two revenue lines are on record. Analytical Instrumentation Sales are the primary driver. The others are software/Subscription Services.
Who are RedShift BioAnalytics's main competitors?
Direct peers on record are Unchained Labs, Waters Corporation, Repligen Corporation and Applied Photophysics. Broad incumbents are Bruker Corporation, Cytiva (Danaher), Agilent Technologies, Thermo Fisher Scientific and Sartorius AG. Fluidic Analytics is listed as an emerging player.
Does RedShift BioAnalytics have an API?
No public API is recorded for RedShift BioAnalytics.
What industry is RedShift BioAnalytics in?
RedShift BioAnalytics's product category is Bioanalytical Instrumentation. Its primary akta.pro industry code is HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.